Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<ul><li>An investment of 10,000 in Kwality Pharmaceuticals’ stock at the start of the year would be worth ₹1.55 lakh today.</li><li>The <keyword id="12239624" type="General" weightage="20" keywordseo="remdesivir-maker" source="Orion">Remdesivir maker</keyword>’s net profit jumped 81% in FY21 to ₹14.88 crore from ₹8.20 crore in FY20.</li><li>The company has an ongoing research &amp; development project of ₹31 crore in Punjab that will be completed by September 2022.</li></ul>Stocks of drug makers have been on a tear but none more than the Punjab-based Kwality Pharmaceuticals. The stock has spiralled from ₹59 in January 2021 to ₹922 today, an addition of ₹863 rupees. An investment of 10,000 in <keyword id="12226938" type="General" weightage="20" keywordseo="kwality-pharma" source="Orion">Kwality Pharma</keyword> at the start of the year would be worth ₹1.55 lakh today. One of its lead products has been Remdesivir, whose demand shot through the roof, as many doctors prescribed the drug to provide relief to COVID-19 patients even when it was not a proven cure against the virus. <div type="image" title="kwality chart" height="900" width="1200" msid="86750900" hostid="261"></div> The exemplary returns in the stock can be attributed to strong profits booked by the company in the last couple of years. In FY21, the company’s net profit jumped 81% to ₹14.88 crore from ₹8.20 crore in FY20. The company is a prominent manufacturer and supplier of pharmaceutical formulations such as liquid orals, powder for oral suspension, tablets, capsules, sterile powder for injections, small volume injectables, ointments, external preparations, ORS, and many other products. “Kwality Pharmaceuticals as an exporting company has supplied Remdesivir Injection to the global market...The sale has gone up and it will keep on growing as many traders and the government have come to know about the medicine(s) of Kwality Pharmaceuticals.The company has also improved the infrastructure and plant &amp; machinery which can meet the global demand,” the company said in its annual report. <div type="image" title="kwality revenue" height="900" width="1200" msid="86750917" hostid="261"></div> Besides, the company has an ongoing research &amp; development project of ₹31 crore in Punjab that will be completed by September 2022. Previously, there was an expansion project of ₹19 crore. The company has improved its infrastructure in order to meet global demand for some of its popular products on time, especially those that emerged during covid. Here is how the company’s peers performed in 2021 as compared to Kwality Pharma: <table style="border-width: initial; border-style: none; table-layout: fixed; width: 468pt;"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Stocks </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">% returns in 2021 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Sun Pharmaceuticals </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">39% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Divi’s Laboratories </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">35% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Dr Reddy’s Labs </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">-3% </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cipla </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">16% </td></tr></tbody></table> More than 30 years passed before the big boom The current managing director of the company, Ramesh Arora, broke away from his family ventures in spinning and aromatics to seek a drug licence that he got in 1981. Kwality Pharma was set up in May 1983. According to the website, the company has two manufacturing plants, one in Amritsar (Punjab) and the other in Jassur (Himachal Pradesh), and has its <a href="https://kwalitypharma.com/about-us.php">products registered</a> in different countries of Europe, Africa, Asia, Central American, and South American Countries &amp; CIS Countries. It’s a largely family controlled organisation with Ramesh’s wife, brother and his wife, as well as his nephew (who is also the Chief Financial Officer), occupying seats on the board of directors. The company had 496 employees at the end of March 2021, according to the annual report. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/thelife/personalities/news/murali-divi-the-billionaire-scientist-behind-divis-labs-is-richer-by-6-billion-and-counting-since-the-pandemic/articleshow/86749881.cms">Murali Divi, the billionaire scientist behind Divi’s Labs, is richer by $6 billion and counting since the pandemic</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/corporates/news/adani-green-shares-jump-as-the-group-adds-5-gigawatts-of-renewable-energy-capacity-with-a-3-5-billion-deal-with-softbank-and-bharti-group/articleshow/86746182.cms">Adani Green shares jump as the group adds 5 gigawatts of renewable energy capacity with a $3.5 billion deal with Softbank and Bharti Group</a>

Thanks to Remdesivir, Kwality Pharma’s stock is up from ₹59 to over ₹922 in just over nine months

<keyword id="20026907" type="General" weightage="20" keywordseo="sun-pharma" source="keywords">Sun Pharma</keyword>ceutical Industries on Thursday said it will acquire the remaining 21.52% stake in Israel-based <keyword id="20238726" type="General" weightage="100" keywordseo="taro" source="keywords">Taro</keyword> Pharmaceutical Industries for Rs 2,891.76 crore, enabling the merger of the two entities. The acquisition of 8,086,818 shares (21.52%) will be at the cost of Rs 2,891.76 crore, Sun Pharma said. The Mumbai-based drug major has agreed to acquire all of the outstanding ordinary shares of Taro for USD 43 per share in cash without interest, as per the definitive merger agreement. Sun Pharma already owns a 78.48% stake in Taro. "Over the years, with Sun Pharma's strategic interventions, Taro has remained a key player in the generic dermatology market in a challenging environment," Sun Pharma Managing Director <keyword id="207035" type="General" weightage="20" keywordseo="Dilip-Shanghvi" source="Orion">Dilip Shanghvi</keyword> said in a statement. After the merger, the combined entity will firmly move forward, leveraging its global strengths and capabilities to better serve the needs of patients and healthcare professionals, he added. Upon completion of the merger, currently expected to close in the first half of 2024, Taro will become a privately held company and its shares will no longer be listed on the NYSE. "Taro is committed to delivering high-quality products to our patients and customers around the world. This merger will further enable us to compete effectively in our products and markets," Taro CEO <keyword id="372826" type="General" weightage="20" keywordseo="Uday-Baldota" source="Orion">Uday Baldota</keyword> said. The merger agreement was unanimously recommended by the Special Committee, which was formed by Taro's Board of Directors to consider Sun Pharma's proposal. Upon receiving the unanimous recommendation of the Special Committee, and following unanimous approval by Taro's Audit Committee, Taro's Board and the Board of Directors of Sun Pharma unanimously approved the definitive merger agreement. Sun Pharma said the USD 43 per share purchase price represents a 48% premium over the closing price of USD 28.97 per share on May 25, 2023, the last trading day before Sun Pharma first submitted its non-binding proposal to Taro. The purchase price also represents a 13% increase over the initial proposed purchase price of USD 38 per share as proposed on May 26, 2023. Sun Pharma shares were trading 1.52% up at Rs 1,319 apiece on BSE.

Sun Pharma to acquire remaining 21.5% shares of Israel-based Taro for Rs 2,892 crore

You Searched For "kwality pharma share price" and got 2 results

Thanks to Remdesivir, Kwality Pharma’s stock is up from ₹59 to over ₹922 in just over nine months

Bhakti Makwana

Sun Pharma to acquire remaining 21.5% shares of Israel-based Taro for Rs 2,892 crore

PTI

Popular Keywords

Buying Guides